« Return to News | Clinical Intelligence

FDA approves Biogen Idec’s Tecfidera for multiple sclerosis

Friday, March 29, 2013 01:44 PM

The FDA has approved Biogen Idec’s Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS).

"No drug provides a cure for multiple sclerosis so it is important to have a variety of treatment options available for patients," said Russell Katz, M.D., director of the division of neurology products in the FDA's Center for Drug Evaluation and Research. "Multiple sclerosis can impair movement, sensation and thinking, and have a profound impact on a person's quality of life."

Results from two clinical trials showed that those taking Tecfidera had fewer MS relapses compared to people taking a placebo. One of the trials showed that those taking Tecfidera experienced a worsening of disability less often than patients taking a placebo.  

Tecfidera may decrease a person's white blood cell count (lymphocytes). Lymphocytes help protect the body from infection and low counts can raise the risk of infection, although no significant increase in infections was seen in patients taking Tecfidera in clinical trials. The most common adverse reactions were flushing, nausea, vomiting and diarrhea, especially at the start of therapy. These side effects may decrease over time.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.